ArticleInternational journal of cardiology. Heart & vasculature2025
Fibrinogen-to-albumin ratio as a novel biomarker for risk assessment in clinically suspected acute myocarditis.
Article in International journal of cardiology. Heart & vasculature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Highlights recently published in the International Journal of Cardiology Heart & Vasculature on sex differences in susceptibility, manifestation and outcome of cardiovascular diseases.International journal of cardiology. Heart & vasculature · 2026Article
- A novel parameter for risk stratification in patients with takotsubo syndrome.American heart journal plus : cardiology research and practice · 2026Article
- Predictors of Outcomes in Patients With Clinically Suspected Myocarditis: Analysis From a Single Center Registry.Reviews in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute myocarditis typically follows a benign course, but fatal complications may occur in fulminant cases. Evaluation is based on clinical, laboratory, and imaging parameters. We aimed to assess the prognostic value of the fibrinogen-to-albumin ratio (FAR) in patients with clinically suspected myocarditis. Methods: Echocardiographic, laboratory, and clinical parameters were obtained from patients with clinically suspected myocarditis. We assessed the correlations between troponin, albumin, fibrinogen, FAR, left ventricular ejection fraction (LVEF), and complications during the index hospitalization. Repeat echocardiography was performed in patients with reduced LVEF. Several potential factors were tested for their ability to predict LVEF recovery. Results: A total of 118 patients were included (80 % male; median age, 35 years; mean LVEF, 55 %). Median troponin level was 2558 ng/L, and the median fibrinogen-to-albumin ratio (FAR) was 120. In 38 patients (32 %), LVEF was reduced; among them, 15 (39 %) had persistently reduced LVEF on repeat echocardiography. Troponin levels and FAR were inversely correlated with reduced LVEF (r = -0.28, p = 0.002 and r = -0.31, p = 0.001, respectively). FAR remained an independent factor after adjustment for age and sex. Neither troponin nor FAR was associated with persistently reduced LVEF on follow-up echocardiography. In addition, high FAR was not correlated with longer length of stay (LOS) (p = 0.07), readmissions (p = 0.29), or complications during hospitalization (p = 0.22). Conclusion: FAR is associated with reduced LVEF and may reflect disease severity in clinically suspected myocarditis; however, it does not appear to be useful for long-term prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.